Gilead Sciences (NASDAQ:GILD) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q 2023) Earnings per share (EPS) missed analyst estimates by 74%. Looking ahead, revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.